The Government of Canada, through the COVID-19 Immunity Task Force (CITF), is supporting a study that will investigate COVID-19 among the Orthodox Jewish community in the Montreal-area, which has been disproportionately affected by COVID-19.
New study will assess impact of COVID-19 vaccination on Canadians with immune-mediated inflammatory disease
More than 7 million Canadians suffer from immune-mediated inflammatory diseases (IMID) such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and related conditions. It is important that they too be protected from COVID-19, yet the effectiveness and safety of vaccines for Canadians with these health issues has not been thoroughly investigated. The COVID-19 Immunity Task Force (CITF) and Vaccine Surveillance Reference Group (VSRG) are supporting a nationwide study that will assess COVID-19 vaccine effectiveness, safety and vaccine hesitancy in this potentially vulnerable group of people.
The COVID-19 Immunity Task Force (CITF) and the Vaccine Surveillance Reference Group (VSRG) are announcing a new study led by Sunnybrook researchers, which seeks to better understand the effectiveness of COVID-19 vaccination in patients with chronic kidney disease.
A national survey has found that at the start of the COVID-19 vaccine rollout, most Canadians planned to get vaccinated, but that intentions were lower among certain demographic groups, including residents of Alberta, Manitoba and Saskatchewan, individuals without a university degree, and racialized Canadians.
Study results show subtle differences in antibody response between Pfizer and Moderna vaccines for residents of long-term care
This CITF-funded research, which is in pre-print, was led by Lunenfeld-Tanenbaum Research Institute (LTRI) senior scientists Dr. Anne-Claude Gingras and Dr. Allison McGeer and reveals that long-term care (LTC) residents in Ontario who received the Pfizer vaccine had lower antibody responses to Alpha, Beta and Gamma than those vaccinated with the Moderna vaccine. The Delta variant was not assessed.
A national research study has just launched to investigate the effectiveness and safety of COVID-19 vaccines in transplant recipients. The Government of Canada, through its COVID-19 Immunity Task Force (CITF) and Vaccine Surveillance Reference Group (VSRG), is investing over $2.84 million in this research study, based at University Health Network and called PREVenT COVID, short for Prospective Evaluation of COVID-19 Vaccine in Transplant Recipients: A National Strategy.
How well do COVID-19 vaccines work in people with cancer, immune deficiencies and other populations with health vulnerabilities?
The Government of Canada, through its COVID-19 Immunity Task Force (CITF) and Vaccine Surveillance Reference Group (VSRG), is investing more than $8 million on four studies led by researchers at The Ottawa Hospital and the University of Ottawa. The studies aim to answer important questions about COVID-19 vaccines, including how well they work in people with cancer and with inherited and medication-related immune deficiencies. One of the studies will also be looking at post-COVID-19 conditions.
Researchers to investigate vaccine uptake, efficacy and side effects in vulnerable urban populations
Urban centres across Canada are home to many vulnerable populations who are more at risk of acquiring SARS-CoV-2 and developing serious complications from COVID-19. The Government of Canada, through the COVID-19 Immunity Task Force (CITF) and the Vaccine Surveillance Reference Group (VSRG), is investing approximately $770,000 in a new study that will investigate the uptake, effectiveness, and side effects of COVID-19 vaccines among members of vulnerable urban populations in Canada.
Canadian researchers to study best approaches to possible adverse events following COVID-19 vaccination
The Government of Canada, through its COVID-19 Immunity Task Force (CITF) and Vaccine Surveillance Reference Group (VSRG), is investing approximately $800,000 for a study that aims to further improve Canada’s identification and response to adverse events people may experience following COVID-19 vaccination across 10 provinces.
A new research study aims to uncover why Montreal North has been one of Canada’s most severely affected neighbourhoods during the COVID-19 pandemic. The study results will shed light on the reasons why some neighbourhoods appear to be at greater risk for the spread of SARS-CoV-2, the virus that causes COVID-19.